NDA 211728 · Urogen Pharma
Jelmyto
Mitomycin · Pyelocalyceal
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Oct 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 15, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
286
89 Phase 3, 41 recruiting
FAERS reports
3,208
2,668 serious, 398 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 9, 2025.
JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 )
Mechanism: Mitomycin inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2020 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
- JELMYTO · MITOMYCIN 40MG/VIAL · POWDER, PYELOCALYCEAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mitomycin" as an intervention, any sponsor and status, largest first.
- Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast CancerPivotal-lookingCompleted
University Hospital BirminghamAcademic, hospital or other
NCT00003893 · 2,250 participants (planned) · Start Jul 1998
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom
- Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung CancerPivotal-lookingStatus unknown
National Cancer Institute (NCI)NIH
NCT00003240 · 1,800 participants (planned) · Start Oct 1995
Drug: cisplatin; ifosfamide and 4 more · For: Lung Cancer
Sites: London, United Kingdom
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
- Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon CancerPivotal-lookingRecruiting
Maimónides Biomedical Research Institute of CórdobaAcademic, hospital or other
NCT06783491 · 1,083 participants (planned) · Start May 26, 2026 · Primary completion Jun 1, 2030
Drug: Mitomycin (MM); FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) · For: Locally Advanced Colorectal Cancer
Sites: Córdoba, Spain
- Trial of Adjuvant Chemotherapy for Gastric CancerPivotal-lookingCompleted
Asan Medical CenterAcademic, hospital or other
NCT00296335 · 855 participants · Start Feb 2002 · Primary completion Nov 2007
Drug: Mitomycin, doxifluridine and cisplatin; Mitomycin and doxifluridine · For: Stomach Cancer
Sites: Seoul, South Korea
- Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural MesotheliomaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00075699 · 840 participants (planned) · Start Sep 2003
Drug: cisplatin; mitomycin C and 2 more · For: Malignant Mesothelioma
Sites: Leeds, United Kingdom; London, United Kingdom; Sutton, United Kingdom
- Laser-1st vs Drops-1st for Glaucoma and Ocular HypertensionPivotal-lookingCompleted
Moorfields Eye Hospital NHS Foundation TrustAcademic, hospital or other
NCT03395535 · 718 participants · Start Oct 1, 2012 · Primary completion Dec 25, 2017
Drug: Primary Medical Treatment Pathway · For: Primary Open Angle Glaucoma; Ocular Hypertension
Sites: London, United Kingdom
- Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical CancerPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00003209 · 700 participants (planned) · Start Dec 1997 · Primary completion Dec 1999
Drug: bleomycin sulfate; cisplatin and 6 more · For: Cervical Cancer
Sites: Derby, United Kingdom; Glasgow, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use384
- nausea165
- diarrhoea158
- fatigue118
- thrombocytopenia112
- vomiting111
- neutropenia109
- drug ineffective108
- rash107
- pancytopenia104
- disease progression100
- pyrexia95
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 77 |
| 2006 | 86 |
| 2007 | 96 |
| 2008 | 125 |
| 2009 | 79 |
| 2010 | 94 |
| 2011 | 137 |
| 2012 | 134 |
| 2013 | 129 |
| 2014 | 86 |
| 2015 | 112 |
| 2016 | 97 |
| 2017 | 86 |
| 2018 | 127 |
| 2019 | 160 |
| 2020 | 157 |
| 2021 | 186 |
| 2022 | 212 |
| 2023 | 148 |
| 2024 | 252 |
| 2025 | 342 |
| 2026 | 219 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Jelmyto (Mitomycin) · HCPCS J9281
2024 spending
$35.3M
Beneficiaries
377
1,607 claims
Per beneficiary
$93,546
2024 ASP limit $303.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $26,431,754 |
| 2022 | $29,464,809 |
| 2023 | $38,116,311 |
| 2024 | $35,266,741 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Impact of Post-Surgical Therapies on Endoscopic and External Dacryocystorhinostomy: Systematic Review and Meta-Analysis.
Vinciguerra A, Nonis A, Resti AG, et al. · Am J Rhinol Allergy 2020 · Meta-Analysis, Systematic Review
- Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA, Winter KA, Gunderson LL, et al. · JAMA 2008 · Clinical Trial, Phase III, Comparative Study
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD, Glynne-Jones R, Meadows HM, et al. · Lancet Oncol 2013 · Clinical Trial, Phase III, Comparative Study
- Efficacy of mitomycin-C on anterior urethral stricture after internal urethrotomy: A systematic review and meta-analysis.
Irdam GA, Wahyudi I, Andy A · F1000Res 2019 · Systematic Review
- Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL, Winter KA, Ajani JA, et al. · J Clin Oncol 2012 · Clinical Trial, Phase III, Multicenter Study
- Capecitabine in the treatment of anal squamous cell carcinoma.
Radka L, Zdeka P · Klin Onkol 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Urogen Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.